Reminder10 Jul 2020 22:38
“If successful, we would hope to protect the lungs and prevent the development of the severe lower respiratory tract illness, which puts the healthcare system under such strain. We have also been pleased with the progress of the SG016 trial in the hospital environment, having dosed 98 of 100 patients, and look forward to announcing top line data in July.”